Why Praxis Precision Medicines, Inc.’s (PRAX) Stock Is Up 7.01%
As of Monday, October 19, Praxis Precision Medicines, Inc.’s PRAX share price has surged by 7.01%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Stock Evaluator: Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. PRAX
$285.93
-2.69
-0.93%
October 30, 2026 4:00:00 PM
EST
Volume: 306,411
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Praxis Precision Medicines, Inc.’s (PRAX) Stock Is Up 6.75%
As of Thursday, October 15, Praxis Precision Medicines, Inc.’s PRAX share price has surged by 6.75%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Praxis Precision Medicines, Inc.’s (PRAX) Stock Is Down 5.39%
As of Thursday, October 08, Praxis Precision Medicines, Inc.’s PRAX share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Michael Rose
Why Praxis Precision Medicines, Inc.’s (PRAX) Stock Is Down 5.11%
As of Monday, October 05, Praxis Precision Medicines, Inc.’s PRAX share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Praxis Precision Medicines, Inc.’s (PRAX) Stock Is Down 6.92%
As of Wednesday, September 23, Praxis Precision Medicines, Inc.’s PRAX share price has dipped by 6.92%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | PRAX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7,979.9 | $226.9 | 75% |
|
| Shares Out (Mil) | 29.1 | 53.4 | 37% |
|
| Institutional Ownership | 99.8% | 92.9% | 94% |
|
| Float (Mil) | 24.1 | 40.7 | 32% |
|
| Beta | 2.78 | 0.95 | 97% |
|
| Avg Daily Volume (000s) | 490 | 469 | 58% |
|
| Price Change (52-week) |
46.0% | 46.6% | 84% |
|
| Growth | PRAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (37.5%) | (10.1%) | 10% |
|
| EPS (5yr) | 35.2% | 15.8% | 85 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (56.9%) | (15.7%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 19 | 19 | 18 | |
| Current EPS | ($3.635) | ($14.024) | ($9.502) | |
| Month Ago EPS | ($3.632) | ($13.935) | ($9.294) | |
| # Rev Up | 0 | 2 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($4.026) | ($15.323) | ($9.656) | |
| Year/Year Chg | 26.5% | 4.1% | (155.2%) | |
| Financials | PRAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($339) | ($44) | 4% |
|
| EPS (TTM) | ($12.858) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($305) | ($33) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $317 | $2 | 88% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $6,974 | $174 | 68% |
|
| Valuation | PRAX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.95 | 2.17 | 83% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PRAX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.6% | na |
|
| Net Margin | na | (71.5%) | na |
|
| ROA | (36.8%) | (47.1%) | 14% |
|
| ROE | (38.9%) | (53.0%) | 18% |
|
| Liabilities to Assets | 3.5% | 29.6% | 1% |
|
| F-Score | 3 | 2 | 18% |
|
Praxis Precision Medicines, Inc. did not pass any screens on 10/30/2026.
